Cargando…

Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity

PD-L1 has two receptors: PD-1 and CD80. Previous reports assumed that PD-L1 and CD80 interacted in trans, but recent reports showed that only cis PD-L1/CD80 interactions existed, and prevention of cis PD-L1/CD80 interactions on antigen-presenting cells (APCs) reduced antitumor immunity via augmentin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yuankun, Song, Qingxiao, Cassady, Kaniel, Lee, Michael, Tang, Haidong, Zheng, Moqian, Wang, Bixin, Schones, Dustin E., Fu, Yang-Xin, Riggs, Arthur D., Martin, Paul J., Feng, Ru, Zeng, Defu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2023
Materias:	Biological sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120074/ https://www.ncbi.nlm.nih.gov/pubmed/37036990 http://dx.doi.org/10.1073/pnas.2205085120

Ejemplares similares

Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80
por: Cassady, Kaniel, et al.
Publicado: (2018)

Donor T cell STAT3 deficiency enables tissue PD-L1–dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity
por: Li, Qinjian, et al.
Publicado: (2023)

Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma
por: Wang, Xiaoqi, et al.
Publicado: (2021)

Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity
por: Song, Qingxiao, et al.
Publicado: (2022)

microRNA-142 guards against autoimmunity by controlling T(reg) cell homeostasis and function
por: Wang, Wei-Le, et al.
Publicado: (2022)

Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model
por: Yamaguchi, Izumi, et al.
Publicado: (2019)

Inhibition of galectin‐3 augments the antitumor efficacy of PD‐L1 blockade in non‐small‐cell lung cancer
por: Zhang, Hongxin, et al.
Publicado: (2021)

Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance
por: Liang, Yong, et al.
Publicado: (2018)

Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8(+) T cell antitumor immunity
por: Li, Anqi, et al.
Publicado: (2022)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
por: Xu-Monette, Zijun Y., et al.
Publicado: (2017)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
por: Hung, Alice L., et al.
Publicado: (2018)

Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer
por: Huang, Kevin Chih-Yang, et al.
Publicado: (2020)

TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair
por: Feng, Yimei, et al.
Publicado: (2019)

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
por: Qin, Wan, et al.
Publicado: (2020)

Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer
por: Lang, Liwei, et al.
Publicado: (2021)

Photothermally sensitive gold nanocage augments the antitumor efficiency of immune checkpoint blockade in immune “cold” tumors
por: Xiao, Guixiu, et al.
Publicado: (2023)

PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model
por: Li, Yuan, et al.
Publicado: (2018)

Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity
por: Villarreal, Daniel O., et al.
Publicado: (2017)

Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination
por: Feng, Yimei, et al.
Publicado: (2022)

Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immunome evaluation
por: You, Wenjie, et al.
Publicado: (2020)

Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer
por: Ma, Yangyang, et al.
Publicado: (2023)

Lenvatinib or anti-VEGF in combination with anti–PD-1 differentially augments antitumor activity in melanoma
por: Tran, Thuy T., et al.
Publicado: (2023)

Polyamine blockade promotes antitumor immunity
por: Hayes, Candace S, et al.
Publicado: (2014)

PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
por: Ali, Lestat R., et al.
Publicado: (2023)

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
por: Lewis, Katherine E., et al.
Publicado: (2017)

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
por: Greco, Rita, et al.
Publicado: (2020)

Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle
por: Oh, Se Jin, et al.
Publicado: (2022)

Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
por: Yadavilli, Sapna, et al.
Publicado: (2023)

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
por: Ye, Jian, et al.
Publicado: (2023)

Intrinsic PD‐L1 promotes antitumor activity of CD8(+) cytotoxic T lymphocytes via in cis interaction with CD80
por: Ding, Yuming, et al.
Publicado: (2022)

The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside
por: Feng, Yimei, et al.
Publicado: (2021)

Correction: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
por: Ali, Lestat R., et al.
Publicado: (2023)

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
por: Della Corte, Carminia Maria, et al.
Publicado: (2019)

Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade
por: Kowalsky, Stacy J., et al.
Publicado: (2018)

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
por: Fang, Douglas D., et al.
Publicado: (2019)

High Plus Low Dose Radiation Strategy in Combination with TIGIT and PD1 Blockade to Promote Systemic Antitumor Responses
por: Barsoumian, Hampartsoum B., et al.
Publicado: (2022)

Steroid-Refractory Gut Graft-Versus-Host Disease: What We Have Learned From Basic Immunology and Experimental Mouse Model
por: Song, Qingxiao, et al.
Publicado: (2022)

Blockade of high mobility group box 1 augments antitumor T‐cell response induced by peptide vaccination as a co‐adjuvant
por: Waki, Kayoko, et al.
Publicado: (2016)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
por: Abe, Shinya, et al.
Publicado: (2022)

Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assay
por: Lema, Diego A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hvkjk3enleea90fdpoedc2cr7u